

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/655,109
		Filing Date	September 5, 2000
		First Named Inventor	Noteborn et al.
		Group Art Unit	1632
		Examiner Name	J. Weitach
Sheet 1 of 4	Attorney Docket Number	2906-4995US	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
JW		US-6,878,692	04-12-2005	Noteborn et al.	
		US-5,981,205	11-1999	Hemmings et al.	
		US-6,809,189 B2	10-26-2004	Noteborn et al.	
		US- 2003/0105315 A1	06-05-2003	Specht et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
JW		EP0921192A1	06-1999	Leadd B.V.		
		EP0924296A2	06-1999	Leadd B.V.		

Examiner Signature		Date Considered	9/29/05
-----------------------	--	--------------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	09/655,109
Filing Date	September 5, 2000
First Named Inventor	Noteborn et al.
Group Art Unit	1632
Examiner Name	J. Weitach
Attorney Docket Number	2906-4995US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
su		Zhuang et al., Apoptin, a Protein Derived from Chicken Anemia Virus, Induces p53-independent Apoptosis in Human Osteosarcoma Cells, Cancer Res, February 1995, pp. 486-89, Vol. 55, No. 3.	
		Pietersen et al., Specific tumor-cell killing with adenovirus vectors containing the apoptin gene, Gene Therapy, 1999, pp. 882-92, Vol. 6.	
		Bellamy, Christopher O.C., et al., "Cell death in health and disease: the biology and regulation of apoptosis," Seminars in Cancer Biology, vol. 6, pp. 3-16 (1995).	
		Danen-Van Oorschot, A.A.A.M., et al., "Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells." Proc. Natl. Acad. Sci. USA vol. 94, pp. 5843-5847 (May 1997).	
		Danen-van Oorschot, et al., A.A.A.M., "BAG-1 inhibits p53-induced but not apoptin-induced apoptosis," Apoptosis, vol. 2, No. 4, pp 395-402 (1997).	
		Duke, Richard C., et al, "Cell Suicide in Health and Disease," Scientific American, pp 80-87 (Dec. 1996).	
		Noteborn, M.H.M., et al., "A Single Chicken Anemia Virus Protein Induces Apoptosis," Journal of Virology, vol. 68, No. 1, pp. 346-351 (Jan. 1994).	
		Noteborn, M.H.M., et al., "Characterization of Cloned Chicken Anemia Virus DNA That Contains All Elements for the Infectious Replication Cycle." Journal of Virology, vol. 65, No. 6, pp. 3131-3139 (Jun. 1991).	
		Noteborn, Mathieu H.M., et al, "Chicken Anemia Virus Induction of Apoptosis by a Single Protein of a Single-Stranded DNA Virus," Seminars in Virology, vol 8, pp 497-504 (1998).	

Examiner  
SignatureDate  
Considered

9/28/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of


4

**Complete if Known**

Application Number	09/655,109
Filing Date	September 5, 2000
First Named Inventor	Noteborn et al.
Group Art Unit	1632
Examiner Name	J. Weitach
Attorney Docket Number	2906-4995US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JW		Noteborn, Mathieu H.M., et al., "Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope," Journal of General Virology, vol. 79, pp. 3073-3077 (1998).	
		Paulovich, Amanda G., et al., "When Checkpoints Fail," Cell, vol. 88, pp 315-321 (Feb. 7, 1997).	
		Steller Hermann, "Mechanisms and Genes of Cellular Suicide," Science, vol. 267, pp 1445-1449 (Mar. 10, 1995).	
		Teodoro, Jose G, et al., "Regulation of Apoptosis by Viral Gene Products," Journal of Virology, vol. 71, No 3, pp 1739-1746 (Mar. 1997).	
		Thompson, Craig B, "Apoptosis in the Pathogenesis and Treatment of Disease," Science, vol. 267, pp 1456-1462 (Mar. 10, 1995).	
		Strausberg, Robert, "qy85c09.x1 NCI_CGAP_Brn25 Homo sapiens cDNA clone IMAGE:2018800 3', mRNA sequence," Jan. 7, 1999, Accession No. AI360308.	
		Zhao S., "Use of BAC End Sequences from Library RPCI-11 for Sequence-Ready Map building," March 15, 1999, ACCESSION NUMBER AQ382839.	
		Strausberg, Robert, "wd70d04.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE:2336935 3', mRNA sequence," June 3, 1999, ACCESSION NUMBER AI692778.	
		Benet et al., pp. 3-32, in The Pharmacological Basis of Therapeutics, 8th ed., McGraw-Hill, Inc., New York, 1990.	
		Jain et al., Vascular and interstitial barriers to delivery of therapeutic agents in tumors, Cancer and Metastasis Reviews, 1990, pp. 253-266, Vol. 9.	
		Jain R.K., Delivery of Molecular Medicine to Solid Tumors, 1996, Science, pp. 1079-1080, Vol. 271.	
		Dermer, Another Anniversary for the War on Cancer, Biotechnology, 1994, pp. 320, Vol. 12.	

Examiner  
Signature

Date  
Considered

9/28/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

Application Number	09/655,109
Filing Date	September 5, 2000
First Named Inventor	Noteborn et al.
Group Art Unit	1632
Examiner Name	J. Weitach
Attorney Docket Number	2906-4995US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JW		Database GenEmbl on GenCore version 4.5, Accession No. AX015052, Oct. 1999.	
		Strausberg R. Database EST on GenCore version 4.5, Accession No. BE746443, Sep. 2000.	
		Danen-Van Oorschot et al., BCL-2 Stimulated Apoptin-induced Apoptosis, pp. 245-249 in Drug Resistance in Leukemia and Lymphoma III, ed. Kaspers et al., Kluwer Academic/Plenum Publishers, New York, 1999.	
		Noteborn et al., Apoptin-induced apoptosis: potential for antitumor therapy, Drug Resistance Updates, 1998, pp. 99-103, Vol. 1.	
		Noteborn et al., Apoptin induces apoptosis in transformed cells specifically: Potentials for an antitumor therapy, Biogenic Amines, 1998, pp. 73-91, Vol. 15, No. 1.	
		Abstract XP-002140967, May 1999.	
		Abstract XP-002140968, May 1995.	
		Abstract XP-002140969, 2000.	
		McDonnell et al., "Implications of apoptotic cell death regulation in cancer therapy," Cancer Biology, 1995, pp. 53-60, vol. 6.	
		Mullersman et al., "The PHD finger: implications for chromatin-mediated transcriptional regulation," TIBS 20, Feb. 1995, pp. 56-59.	
		Jacobson et al., "Modifying chromatin and concepts of cancer," Chromosomes and expression mechanisms, pp. 175-184.	
		Lu et al., "A Novel Gene (PLU-1) Containing Highly Conserved Putative DNA/Chromatin Binding Motifs Is Specifically Up-regulated in Breast Cancer," The Journal of Biological Chemistry, 1999, pp. 15633-15645, Vol. 274, No. 22.	
		Zhuang et al., "Apoptin, a Protein Encoded by Chicken Anemia Virus, Induces Cell Death in Various Human Hematologic Malignant Cells in vitro," Leukemia, vol. 9, Suppl. 1, pp. S118-S120, 1995.	

Examiner  
SignatureDate  
Considered

9/28/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

DOCKET NO. LEBV.008.01US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 2RECEIVED  
JAN 09 2001  
TECH CENTER 1600/2900In re the application of: Noteborn, *et al.*

] ] ] ] ]

Art Unit: 1614

Serial No. 09/655,109

Examiner: Not Yet Assigned

Filed: September 5, 2000

## U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	Filing Date
A1		5,491,073	2/13/1996	Noteborn and deBoer	435/69.1	9/11/1991

## FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Filing Date
B1	90	WO 96/41191	12/19/1996	PCT		6/7/1996
B2		WO 98/46760	10/22/1998	PCT		4/15/1998
B3		WO 99/08108	2/18/1999	PCT		8/11/1998

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
C1	90	Danen-Van Oorschot, <i>et al.</i> (1997) "Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells." <i>Proc Natl Acad Sci, USA</i> : 94, 5843-5847.
C2		Danen-Van Oorschot, <i>et al.</i> (1997) "BAG-1 inhibits p53-induced but not apoptin-induced apoptosis." <i>Apoptosis</i> 2, 395-402.
C3		Garcia, <i>et al.</i> (1999) "RYBP, a new repressor protein that interacts with components of the mammalian polycomb complex, and with the transcription factor YY1." <i>EMBO J</i> 18,

Examiner:

Date Considered:

9/28/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PATENT

DOCKET NO. LEBV.008.01US



COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 2 of 2

In re the application of: Noteborn, *et al.*

Art Unit: 1614

Serial No. 09/655,109

Examiner: Not Yet Assigned

Filed: September 5, 2000

- 92
- C4 ' 3404-3418.  
Kerr, *et al.* (1994) "Apoptosis: Its significance in cancer and cancer therapy." *Cancer* 73, 2013-2026.
- C5 ' Levine, A.J. (1997) "p53, the cellular gatekeeper for growth and division." *Cell* 88, 323-331.
- C6 ' Noteborn, *et al.* (1991) "Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle." *J Virol* 65, 3131-3139.
- C7 ' Noteborn, *et al.* (1994) "A single chicken anemia virus protein induces apoptosis." *J Virol* 68, 346-351.
- C8 ' Noteborn, *et al.* (1998) "Chicken anemia virus: Induction of apoptosis by a single protein of a single-stranded DNA virus." *Seminars in Virology* 8, 497-504.
- C9 ' Paulovich, *et al.* (1997) "When checkpoints fail." *Cell* 88, 315-321.
- C10 ' Pietersen *et al.* (1999) "Specific tumor-cell killing with adenovirus vectors containing the apoptin gene." *Gene Therapy* 6, 882-892.
- C11 ' Zhuang, *et al.* (1995) "Apoptin, a protein derived from chicken anemia virus, induces a p53-independent apoptosis in human osteosarcoma cells." *Cancer Research* 55, 486-489.

Examiner:

Date Considered: 9/28/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.